These findings support our premise that, after therapeutic microwave ablation, residual viable tumor cells can also work as “tumor vaccines” and induce effective antitumor immune responses by upregulating expression of CRT and exploiting the immunostimulatory environment in multiple carcinomas. This evidence concerns the gene CALR and neoplasm.